Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus versus tacrolimus current clinical practice after de novo kidney transplantation
2014-004314-29Phase 4Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2015
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in kidney transplant immunosuppression (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Tacrolimus total daily dose. Started Jan 2015; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2014-004314-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004314-29.